Isovalerylspiramycin I suppresses non-small cell lung carcinoma growth through ROS-mediated inhibition of PI3K/AKT signaling pathway

Novel drugs are required for non-small cell lung cancer (NSCLC) treatment urgently. Repurposing old drugs as new treatments is a practicable approach with time and cost savings. Some studies have shown that carrimycin, a Chinese Food and Drug Administration (CFDA)-approved macrolide antibiotic, poss...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zeyu, Huang, Moli, Hong, Yue, Wang, Shaoyang, Xu, Yongle, Zhong, Cheng, Zhang, Jingyuan, Zhuang, Zhengping, Shan, Shan, Ren, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254468/
https://www.ncbi.nlm.nih.gov/pubmed/35813464
http://dx.doi.org/10.7150/ijbs.69989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254468/
https://www.ncbi.nlm.nih.gov/pubmed/35813464
http://dx.doi.org/10.7150/ijbs.69989

Ejemplares similares